Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 506

1.

Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ; ICICLE-PD study group, Barker RA.

Brain. 2014 Oct;137(Pt 10):2743-58. doi: 10.1093/brain/awu201. Epub 2014 Jul 30.

2.

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA.

Brain. 2009 Nov;132(Pt 11):2958-69. doi: 10.1093/brain/awp245. Epub 2009 Oct 7.

PMID:
19812213
3.

APOE, MAPT, and COMT and Parkinson's Disease Susceptibility and Cognitive Symptom Progression.

Paul KC, Rausch R, Creek MM, Sinsheimer JS, Bronstein JM, Bordelon Y, Ritz B.

J Parkinsons Dis. 2016 Apr 2;6(2):349-59. doi: 10.3233/JPD-150762.

4.

Genetic influences on cognitive decline in Parkinson's disease.

Morley JF, Xie SX, Hurtig HI, Stern MB, Colcher A, Horn S, Dahodwala N, Duda JE, Weintraub D, Chen-Plotkin AS, Van Deerlin V, Falcone D, Siderowf A.

Mov Disord. 2012 Apr;27(4):512-8. doi: 10.1002/mds.24946. Epub 2012 Feb 16.

5.

Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease.

Bäckström D, Eriksson Domellöf M, Granåsen G, Linder J, Mayans S, Elgh E, Zetterberg H, Blennow K, Forsgren L.

Acta Neurol Scand. 2018 Jan;137(1):91-98. doi: 10.1111/ane.12812. Epub 2017 Sep 4.

6.

Association between MAPT haplotype and memory function in patients with Parkinson's disease and healthy aging individuals.

Winder-Rhodes SE, Hampshire A, Rowe JB, Peelle JE, Robbins TW, Owen AM, Barker RA.

Neurobiol Aging. 2015 Mar;36(3):1519-28. doi: 10.1016/j.neurobiolaging.2014.12.006. Epub 2014 Dec 11.

7.

Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study.

Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn DJ, O'Brien JT.

Brain. 2015 Oct;138(Pt 10):2974-86. doi: 10.1093/brain/awv211. Epub 2015 Jul 14.

8.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

9.

Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease.

Hoogland J, de Bie RM, Williams-Gray CH, Muslimović D, Schmand B, Post B.

Mov Disord. 2010 Nov 15;25(15):2550-4. doi: 10.1002/mds.23319.

PMID:
20878993
10.

Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease.

Zhang Y, Feng S, Nie K, Zhao X, Gan R, Wang L, Zhao J, Tang H, Gao L, Zhu R, Wang L, Zhang Y.

J Neurol Sci. 2016 Oct 15;369:347-353. doi: 10.1016/j.jns.2016.08.063. Epub 2016 Aug 31.

PMID:
27653922
11.

Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.

Williams-Gray CH, Hampshire A, Barker RA, Owen AM.

Brain. 2008 Feb;131(Pt 2):397-408. doi: 10.1093/brain/awm313. Epub 2008 Jan 4.

PMID:
18178571
12.

Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?

Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, Brooks DJ, Barker RA, Burn DJ, O'Brien JT.

Mov Disord. 2016 Jan;31(1):103-10. doi: 10.1002/mds.26312. Epub 2015 Jul 22.

PMID:
26202802
13.

[Cognitive impairment in Parkinson's disease].

Tachibana H.

Seishin Shinkeigaku Zasshi. 2013;115(11):1142-9. Review. Japanese.

PMID:
24450147
14.

Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease.

Filoteo JV, Reed JD, Litvan I, Harrington DL.

Mov Disord. 2014 Mar;29(3):360-7. doi: 10.1002/mds.25633. Epub 2013 Sep 3.

15.

Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.

Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM.

Lancet Neurol. 2017 Jan;16(1):66-75. doi: 10.1016/S1474-4422(16)30328-3. Epub 2016 Nov 18.

16.

Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD study.

Minett T, Su L, Mak E, Williams G, Firbank M, Lawson RA, Yarnall AJ, Duncan GW, Owen AM, Khoo TK, Brooks DJ, Rowe JB, Barker RA, Burn D, O'Brien JT.

J Neurol. 2018 Jul;265(7):1528-1539. doi: 10.1007/s00415-018-8873-0. Epub 2018 Apr 25.

PMID:
29696499
17.

Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease.

Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA.

J Neurosci. 2007 May 2;27(18):4832-8.

18.

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P; Parkinson Study Group DATATOP Investigators, Zhang J.

Parkinsonism Relat Disord. 2015 Mar;21(3):271-6. doi: 10.1016/j.parkreldis.2014.12.027. Epub 2015 Jan 5.

19.

Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.

Mata IF, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Espay AJ, Revilla FJ, Devoto J, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Neurobiol Aging. 2017 Aug;56:211.e1-211.e7. doi: 10.1016/j.neurobiolaging.2017.04.009. Epub 2017 Apr 20.

20.

Differential optimal dopamine levels for set-shifting and working memory in Parkinson's disease.

Fallon SJ, Smulders K, Esselink RA, van de Warrenburg BP, Bloem BR, Cools R.

Neuropsychologia. 2015 Oct;77:42-51. doi: 10.1016/j.neuropsychologia.2015.07.031. Epub 2015 Jul 31.

PMID:
26239947

Supplemental Content

Support Center